Why this ASX 200 'stable stock' is poised to outperform: Goldman Sachs

According to analysts at Goldman Sachs, stocks with stable earnings growth and share prices have historically tended to outperform when the economy is slowing.

| More on:
A mature age woman with a groovy short haircut and glasses, sits at her computer, pen in hand thinking about information she is seeing on the screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index (ASX: XJO) healthcare share ResMed Inc (ASX: RMD) counts among a select basket of stable stocks that Goldman Sachs believes is set to widely outperform the benchmark.

The company is listed on multiple international exchanges. It focuses on treating a range of sleeping disorders and has seen some sizeable swings its share price over the past year, leaving it right about where it was 12 months ago.

But the ASX 200 medical stock could enjoy a far stronger year ahead.

14% potential share price upside for ResMed

According to analysts at Goldman Sachs, stocks with stable earnings growth and share prices have historically tended to outperform when the economy is slowing. But we've yet to see that with Goldman's basket of stable stocks, which includes ResMed.

"Our economists see greater downside risks than upside risks, suggesting ample opportunities for stable stocks to outperform," the analysts said (courtesy of The Australian Financial Review.)

The broker said that despite the economic slowdown hitting developed nations, stables stocks — like ASX 200 listed ResMed — are trading at "undemanding valuations".

There are no guarantees in the world of investing. But Goldman sees a positive risk-reward trade-off with ResMed shares.

The main risk to owning stable stocks is if economic growth proves to be more resilient than we expect," the broker said. "But low valuations, poor recent performance, and elevated recession risk mean the risk/reward is asymmetric."

In its recent report profiling a range of ASX 200 healthcare stocks, Goldman noted:

We continue to express a general preference for the device/drug names over the service providers in the current environment, on the basis of: i) stronger pricing power; ii) more assured volume profiles; iii) more resilient/expanding market shares; and iv) stronger balance sheets.

As for ResMed specifically, the analysts said, "As operational pressures continue to ease we see margin/cost dynamics improving, both near and long-term."

Goldman is expecting "a sequentially stronger 2H23" for the ASX 200 medical device stock. The analysts forecast an earnings per share compound annual growth rate of 11% over the next three years "with potential upside depending on how competitive dynamics develop".

Sharper-than-expected competitor recovery and potentially new disruptive therapies are the key risks to this outlook.

Goldman has a buy rating on ResMed shares with a target price of $38.00. That's 13.8% above the current share price.

How has this ASX 200 stable stock been tracking?

As you can see in the chart below, the ResMed share price is just about flat over the past 12 months. So far in 2023, the ASX 200 stable stock has gained 7.8%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »